Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810824 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| Trifluoroacetic Acid SCHEMBL4812305 | 0.92 | ALDH1A1 (0.40) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL1171081 | 0.87 | SMN1; SMN2 (0.42) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL1171079 | 0.87 | SMN1; SMN2 (0.42) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL2435399 | 0.85 | ALDH1A1 (0.43) | ALDH1A1MAPTPOLBSMN1; SMN2CYP3A4 | |
| SCHEMBL2435396 | 0.85 | ALDH1A1 (0.43) | ALDH1A1MAPTPOLBSMN1; SMN2CYP3A4 | |
| SCHEMBL71447 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MAPTPOLBSMN1; SMN2CYP3A4 | |
| SCHEMBL71446 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MAPTPOLBSMN1; SMN2CYP3A4 | |
| SCHEMBL72207 | 0.83 | ALDH1A1 (0.51) | ALDH1A1MAPTPOLBSMN1; SMN2CYP3A4 | |
| SCHEMBL71606 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MAPTPOLBSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-7345179-B2 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20070149607-A1 | Method for producing pyrrolidine derivative | DAICHI PAHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1698621-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1623975-A1 | PROCESS FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | ALDH18A1, PLAAT4, ACSL4 | ALDH1A1 110/4885MAPT 4672/4885POLB 1064/4885 |
| US-20070149607-A1 | Method for producing pyrrolidine derivative | ALDH18A1, PLAAT4, ACSL4 | ALDH1A1 110/4885MAPT 4672/4885POLB 1064/4885 |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | ACSL4, ALDH18A1, LTA | ALDH1A1 139/4885MAPT 4107/4885POLB 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.